NCT06989541View on ClinicalTrials.gov

Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2027

Conditions
Hypogammaglobulinemia, Acquired
Interventions
BIOLOGICAL

Immune Globulin Intravenous (Human), 10%

Intravenous immune globulin replacement

BIOLOGICAL

Immune Globulin Subcutaneous (Human), 20% Solution

Subcutaneous immune globulin replacement

Trial Locations (1)

T6G 2G3

RECRUITING

University of Alberta, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT06989541 - Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy | Biotech Hunter | Biotech Hunter